Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or by accessing the investors section of the company's website within 72 hours.
哈肯萨克,纽约 / ACCESSWIRE / 2024年12月5日 / champions oncology, Inc. (纳斯达克:CSBR),一家提供端到端肿瘤解决方案的全球前临床和临床研究服务提供商,将于2024年12月11日星期三市场关闭后公布截至2024年10月31日的第二季度财务和运营结果。公司将在当天下午4:30(美国东部时间)举行电话会议,讨论结果(下午1:30,太平洋时间)。如要参加会议,请拨打888-506-0062(国内)或973-528-0011(国际),并输入访问代码710610。会议回放可通过拨打877-481-4010(国内)或919-882-2331(国际)并输入密码:51750,或者在公司网站的投资者部分访问,72小时内可用。
About Champions Oncology, Inc.
关于Champions Oncology, Inc。
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit .
champions oncology是全球临床前和临床研究服务提供商,为生物制药组织提供端到端的肿瘤研发解决方案。作为拥有最大、最全面的与临床相关的患者来源异种移植(PDX)和原发性血液恶性肿瘤模型库的公司,champions通过独特的体内和体外平台提供创新的高质量数据。通过其大型先进生物分析平台组合、突破性数据平台和分析以及科学卓越,champions促进了世界范围内临床前和临床肿瘤药物发现与开发项目的进展。欲了解更多信息,请访问。
SOURCE: Champions Oncology, Inc.
SOURCE:Champions Oncology,Inc。